Advertisement Pharmaceutical Business review - Page 321 of 5222 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 27, 2024

Acumen Pharmaceuticals extends collaboration with Lonza for sabirnetug

Acumen Pharmaceuticals has announced the extension of its collaboration with Lonza to facilitate the anticipated commercial launch of sabirnetug, a new therapeutic for early Alzheimer's disease (AD).

Lonza is already involved in the drug substance manufacturing for the Phase II clinical supply of the antibody. Credit: Steve Buissinne from Pixabay.